{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:46:57Z","timestamp":1762303617622,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006376","name":"Georgia Southern University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007864","name":"Brandeis University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.drugalcdep.2025.112616","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T19:10:42Z","timestamp":1739819442000},"page":"112616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluation of an in-jail and post-release comprehensive treatment model for opioid use disorder in Massachusetts"],"prefix":"10.1016","volume":"270","author":[{"given":"Peter J.","family":"Koutoujian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7974-9177","authenticated-orcid":false,"given":"Robert M.","family":"Bohler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6641-7664","authenticated-orcid":false,"given":"Thomas","family":"Senst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kashif","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haresh","family":"Rochani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Kolodny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112616_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/sim.8399","article-title":"A review of the use of time-varying covariates in the Fine-Gray subdistribution hazard competing risk regression model","volume":"39","author":"Austin","year":"2020","journal-title":"Stat. Med."},{"issue":"10","key":"10.1016\/j.drugalcdep.2025.112616_bib2","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40264-018-0705-8","article-title":"Potential risk windows for opioid overdose related to treatment with extended-release injectable naltrexone","volume":"41","author":"Binswanger","year":"2018","journal-title":"Drug Saf."},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112616_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMsa064115","article-title":"Release from prison\u2014a high risk of death for former inmates","volume":"356","author":"Binswanger","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2025.112616_bib4","unstructured":"Bronson, J., Stroop, J., Zimmer, S., & Berzofsky, M. 2017. Drug use, dependence, and abuse among state prisoners and jail inmates, 2007\u20132009. Washington, DC: United States Department of Justice, Office of Juvenile Justice and Delinquency Prevention. \u3008https:\/\/bjs.ojp.gov\/content\/pub\/pdf\/dudaspji0709.pdf\u3009"},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112616_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.7036","article-title":"Estimated costs and outcomes associated with use and nonuse of medications for opioid use disorder during incarceration and at release in Massachusetts","volume":"6","author":"Chatterjee","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.drugalcdep.2025.112616_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109254","article-title":"Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder","volume":"231","author":"Evans","year":"2022","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2025.112616_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108076","article-title":"A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder","volume":"117","author":"Farabee","year":"2020","journal-title":"J. Subst. Abus. Treat."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112616_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13722-021-00266-2","article-title":"The impact of methamphetamine\/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review","volume":"16","author":"Frost","year":"2021","journal-title":"Addict. Sci. Clin. Pract."},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112616_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jamapsychiatry.2017.4614","article-title":"Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system","volume":"75","author":"Green","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2025.112616_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102768","article-title":"A scoping review of barriers and facilitators to implementation of medications for treatment of opioid use disorder within the criminal justice system","volume":"81","author":"Grella","year":"2020","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2025.112616_bib11","article-title":"Fatal and nonfatal opioid overdose risk following release from prison: a retrospective cohort study using linked administrative data","volume":"147","author":"Hartung","year":"2023","journal-title":"J. Subst. Use Addict. Treat."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112616_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13722-019-0145-5","article-title":"A conceptual model for understanding post-release opioid-related overdose risk","volume":"14","author":"Joudrey","year":"2019","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.drugalcdep.2025.112616_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108690","article-title":"Treatment preference for opioid use disorder among people who are incarcerated","volume":"137","author":"Kaplowitz","year":"2022","journal-title":"J. Subst. Abus. Treat."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112616_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.annemergmed.2019.07.014","article-title":"Predictors of overdose death among high-risk emergency department patients with substance-related encounters: a data linkage cohort study","volume":"75","author":"Krawczyk","year":"2020","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2025.112616_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108329","article-title":"Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings","volume":"126","author":"Krawczyk","year":"2021","journal-title":"J. Subst. Abus. Treat."},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112616_bib16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"13","key":"10.1016\/j.drugalcdep.2025.112616_bib17","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.112616_bib18","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/add.12894","article-title":"Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial","volume":"110","author":"Lee","year":"2015","journal-title":"Addiction"},{"issue":"10118","key":"10.1016\/j.drugalcdep.2025.112616_bib19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet (Lond., Engl. )"},{"issue":"408","key":"10.1016\/j.drugalcdep.2025.112616_bib20","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The robust inference for the cox proportional hazards model","volume":"84","author":"Lin","year":"1989","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.drugalcdep.2025.112616_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jsat.2017.04.002","article-title":"Extended-release naltrexone for opioid use disorder started during or following incarceration","volume":"85","author":"Lincoln","year":"2018","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.drugalcdep.2025.112616_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.107858","article-title":"Estimating the impact of wide scale uptake of screening and medications for opioid use disorder in US prisons and jails","volume":"208","author":"Macmadu","year":"2020","journal-title":"Drug Alcohol Depend."},{"issue":"8","key":"10.1016\/j.drugalcdep.2025.112616_bib23","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/add.13779","article-title":"Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England","volume":"112","author":"Marsden","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2025.112616_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jsat.2018.12.003","article-title":"Effectiveness of medication assisted treatment for opioid use in prison and jail settings: a meta-analysis and systematic review","volume":"99","author":"Moore","year":"2019","journal-title":"J. Subst. Abus. Treat."},{"issue":"8","key":"10.1016\/j.drugalcdep.2025.112616_bib25","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/add.13807","article-title":"Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder","volume":"112","author":"Murphy","year":"2017","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.drugalcdep.2025.112616_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232086","article-title":"Retention of patients in opioid substitution treatment: a systematic review","volume":"15","author":"O\u2019Connor","year":"2020","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.112616_bib27","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1037\/adb0000090","article-title":"Predictors of patient retention in methadone maintenance treatment","volume":"29","author":"Proctor","year":"2015","journal-title":"Psychol. Addict. Behav.: J. Soc. Psychol. Addict. Behav."},{"issue":"9","key":"10.1016\/j.drugalcdep.2025.112616_bib28","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2105\/AJPH.2018.304514","article-title":"Opioid overdose mortality among former North Carolina Inmates: 2000\u20132015","volume":"108","author":"Ranapurwala","year":"2018","journal-title":"Am. J. Public Health"},{"issue":"6565","key":"10.1016\/j.drugalcdep.2025.112616_bib29","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.abj7779","article-title":"Toward an understanding of structural racism: implications for criminal justice","volume":"374","author":"Rucker","year":"2021","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.drugalcdep.2025.112616_bib30","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/add.14199","article-title":"Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: vivitrol\u2019s Cost and Treatment Outcomes Registry","volume":"113","author":"Saxon","year":"2018","journal-title":"Addiction"},{"issue":"14","key":"10.1016\/j.drugalcdep.2025.112616_bib31","doi-asserted-by":"crossref","first-page":"382","DOI":"10.15585\/mmwr.mm6614a2","article-title":"Characteristics of Fentanyl Overdose\u2014Massachusetts, 2014-2016","volume":"66","author":"Somerville","year":"2017","journal-title":"Mmwr. Morb. Mortal. Wkly. Rep."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112616_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/QAI.0000000000001634","article-title":"Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV with opioid use disorders transitioning to the community: results of a double-blind, placebo-controlled randomized trial","volume":"78","author":"Springer","year":"2018","journal-title":"J. Acquir. Immune Defic. Syndr. (1999)"},{"key":"10.1016\/j.drugalcdep.2025.112616_bib33","article-title":"Availability of medications for opioid use disorder in U.S. jails","author":"Sufrin","year":"2022","journal-title":"J. Gen. Intern. Med."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.112616_bib34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/epirev\/mxad010","article-title":"We adjusted for race\u201d: Now what? A systematic review of utilization and reporting of race in American Journal of Epidemiology and Epidemiology, 2020-2021","volume":"45","author":"Swilley-Martinez","year":"2023","journal-title":"Epidemiol. Rev."},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112616_bib35","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0306-4522(97)00659-3","article-title":"Quantitative immunolocalization of mu opioid receptors: regulation by naltrexone","volume":"85","author":"Unterwald","year":"1998","journal-title":"Neuroscience"},{"issue":"9","key":"10.1016\/j.drugalcdep.2025.112616_bib36","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/journalofethics.2017.19.9.stas1-1709","article-title":"Why it\u2019s inappropriate not to treat incarcerated patients with opioid agonist therapy","volume":"19","author":"Wakeman","year":"2017","journal-title":"AMA J. Ethics"},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.112616_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112616_bib38","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.0558","article-title":"Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use","volume":"1","author":"Winkelman","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.drugalcdep.2025.112616_bib39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.drugalcdep.2015.06.011","article-title":"Incidence and predictors of non-fatal drug overdose after release from prison among people who inject drugs in Queensland, Australia","volume":"153","author":"Winter","year":"2015","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.112616_bib40","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/1078345819852133","article-title":"Screening for opioid use disorder in the largest jail in Arkansas: a brief report","volume":"25","author":"Zaller","year":"2019","journal-title":"J. Correct. Health Care: Off. J. Natl. Comm. Correct. Health Care"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625000699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625000699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:42:07Z","timestamp":1762303327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871625000699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":40,"alternative-id":["S0376871625000699"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112616","relation":{},"ISSN":["0376-8716"],"issn-type":[{"type":"print","value":"0376-8716"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of an in-jail and post-release comprehensive treatment model for opioid use disorder in Massachusetts","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112616"}}